A Phase 3 interventional study of Sitagliptin and Atorvastatin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-07-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 81st largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 110th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 13 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 89th largest by enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2011, is one of 86 in phase 3, and was the 123rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin alone and sitagliptin alone, respectively. Following a single-blind placebo run-in period, participants were to be randomized to one of three treatment arms (sitagliptin monotherapy, atorvastatin monotherapy, or sitagliptin plus atorvastatin) for 16 weeks (Phase A). During Phase B of the study (Weeks 16 through 54), participants were to receive either sitagliptin plus atorvastatin or glimepiride plus atorvastatin. The primary hypotheses were that after 16 weeks of treatment, sitagliptin in combination with atorvastatin reduces A1C from baseline more than atorvastatin alone, and that atorvastatin in combination with sitagliptin lowers LDL-C from baseline more than sitagliptin alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
Drug: Sitagliptin · Drug: Atorvastatin · Other: Placebo to atorvastatin · Drug: Metformin (open-label) · Drug: Glimepiride (open-label) · Drug: Placebo to glimepiride
In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
Drug: Atorvastatin · Other: Placebo to sitagliptin · Drug: Metformin (open-label) · Drug: Glimepiride (double-blind)
In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
Drug: Sitagliptin · Drug: Atorvastatin · Drug: Metformin (open-label) · Drug: Glimepiride (open-label) · Drug: Placebo to glimepiride
Sitagliptin 100 mg tablet orally daily
Also known as: Januvia
Atorvastatin 80 mg tablet orally daily
Also known as: Lipitor
Placebo to sitagliptin tablet orally daily
Placebo to atorvastatin tablet orally daily.
Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
Also known as: Glucophage
Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
Also known as: Amaryl
Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
Phase B: placebo to glimepiride tablet orally daily.
Change From Baseline in Hemoglobin A1C (A1C) at Week 16
A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 16
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Number of Participants Who Experienced at Least One Adverse Event
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.
Time frame: Up to 56 weeks (including 2-week follow-up)
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.
Time frame: Up to 54 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16
Change from baseline reflects the Week 16 value minus the Week 0 value.
Time frame: Baseline and Week 16
Percent Change From Baseline in Total Cholesterol at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Triglycerides at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Note: 10 participants were enrolled in the study more than once (at more than 1 study site). Nine participants were enrolled twice and one participant was randomized at 3 different sites. Therefore, data of 10 actual participants (counted as 21 participants due to multiple screening/randomization) were removed from the efficacy analyses.
| Milestone | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Started | 55 | 56 | 55 |
| Completed | 12 | 11 | 11 |
| Not completed | 43 | 45 | 44 |
| Withdrew: Adverse event | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 4 | 3 | 2 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 37 | 40 | 39 |
| Milestone | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Started | 12 | 11 | 11 |
| Completed | 0 | 0 | 0 |
| Not completed | 12 | 11 | 11 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 12 | 10 | 11 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent.
| Percent | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 16 | -1.17 ± 0.20 | 0.04 ± 0.31 | -1.01 ± 0.22 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 | 4.9 ± 10.4 | -35.7 ± 7.1 | -38.7 ± 6.6 |
Change from baseline reflects the Week 16 value minus the Week 0 value.
| mg/dL | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16 | -15.7 ± 6.4 | 22.7 ± 10.1 | -26.0 ± 14.0 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 16 | -1.7 ± 6.2 | -28.3 ± 4.8 | -25.7 ± 6.0 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 | -4.8 ± 6.5 | -32.9 ± 5.6 | -29.0 ± 4.6 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 | -1.0 ± 8.8 | -34.4 ± 6.7 | -34.6 ± 6.7 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 16 | -9.9 ± 8.6 | -28.7 ± 6.5 | -10.5 ± 13.5 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16 | -15.5 ± 7.2 | -28.6 ± 6.6 | -10.4 ± 13.5 |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16 | -0.3 ± 3.2 | -5.8 ± 3.5 | 1.5 ± 6.0 |
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.
| Participants | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event | 10 | 13 | 13 |
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an adverse event. Data presented exclude data following the initiation of glycemic rescue therapy.
| Participants | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 1 | 2 | 2 |
Collected over Up to 56 weeks including 2-week follow-up (up to 56 weeks for serious adverse events, up to 54 weeks for non-serious adverse events). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin/Sitagliptin + Atorvastatin | — | 0/55 (0%) | 3/55 (5.5%) |
| Atorvastatin/Atorvastatin + Glimepiride | — | 0/56 (0%) | 3/56 (5.4%) |
| Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin | — | 1/55 (1.8%) | 5/55 (9.1%) |
| Event | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/55 | 0/56 | 1/55 |
| Event | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin |
|---|---|---|---|
| Glomerular filtration rate decreasedInvestigations | 1/55 | 0/56 | 3/55 |
| Intentional overdoseInjury, poisoning and procedural complications | 2/55 | 3/56 | 2/55 |
| Age, Continuous(Years) | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin | Total |
|---|---|---|---|---|
| Mean | 56.2 ± 9.7 | 56.3 ± 8.2 | 53.7 ± 10.0 | 55.4 ± 9.4 |
| Sex: Female, Male(Participants) | Sitagliptin/Sitagliptin + Atorvastatin | Atorvastatin/Atorvastatin + Glimepiride | Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin | Total |
|---|---|---|---|---|
| Female | 24 | 27 | 24 | 75 |
| Male | 31 | 29 | 31 | 91 |
No study locations are listed for this record.
Ran from Oct 2011 to primary completion in Dec 2012, 13 months.
Results were first posted in Oct 2016, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin